Pharmacodynamic Interactions of Propofol and Dexmedetomidine on Intravenous Anesthesia
NCT ID: NCT02777619
Last Updated: 2016-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
64 participants
INTERVENTIONAL
2016-01-31
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of Gender on Interaction of Propofol and Dexmedetomidine
NCT02853864
Dexmedetomidine Versus Propofol for Sedation During Awake Endotracheal Intubation
NCT04753515
Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation.
NCT06327399
Dexmedetomidine Combined With the Closed Loop of Target Controlled Infusion of Propofol for Anesthesia With Intraoperative Wake up
NCT02143362
Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients
NCT01669044
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Propofol and 0.0ng/ml Dexmedetomidine
Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
0.0ng/ml Dexmedetomidine
Dexmedetomidine target plasma concentration is 0.0ng/ml
Propofol
Propofol and 0.4ng/ml Dexmedetomidine
Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
0.4ng/ml Dexmedetomidine
Dexmedetomidine target plasma concentration is 0.4ng/ml
Propofol
Propofol and 0.6ng/ml Dexmedetomidine
Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
0.6ng/ml Dexmedetomidine
Dexmedetomidine target plasma concentration is 0.6ng/ml
Propofol
Propofol and 0.8ng/ml Dexmedetomidine
Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
0.8ng/ml Dexmedetomidine
Dexmedetomidine target plasma concentration is 0.8ng/ml
Propofol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.0ng/ml Dexmedetomidine
Dexmedetomidine target plasma concentration is 0.0ng/ml
0.4ng/ml Dexmedetomidine
Dexmedetomidine target plasma concentration is 0.4ng/ml
0.6ng/ml Dexmedetomidine
Dexmedetomidine target plasma concentration is 0.6ng/ml
0.8ng/ml Dexmedetomidine
Dexmedetomidine target plasma concentration is 0.8ng/ml
Propofol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Written informed consent from the patient or the relatives of the participating patient.
Exclusion Criteria
2. Existing significant haematological, endocrine, metabolic or gastrointestinal disease.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou General Hospital of Guangzhou Military Command
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
bo xu
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou Military Region General Hospital, Department of Anesthesiology
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chen Z, Shao DH, Hang LH. Effects of dexmedetomidine on performance of bispectral index as an indicator of loss of consciousness during propofol administration. Swiss Med Wkly. 2013 Mar 14;143:w13762. doi: 10.4414/smw.2013.13762. eCollection 2013.
Hannivoort LN, Eleveld DJ, Proost JH, Reyntjens KM, Absalom AR, Vereecke HE, Struys MM. Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. Anesthesiology. 2015 Aug;123(2):357-67. doi: 10.1097/ALN.0000000000000740.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pharmacodynamic Interactions
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.